Skip to main content

Advertisement

SpringerLink
Log in

Agitation and Irritability in Alzheimer’s Disease: Evidenced-Based Treatments and the Black-Box Warning

  • Geriatric Disorders (W McDonald, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

More than five million Americans suffer from Alzheimer’s disease (AD), and this number is expected to triple by 2050. While impairments in cognition, particularly memory, are typically the defining features of the clinical syndrome, behavioral symptoms are extremely common, affecting up to 90 % of patients. Behavioral symptoms in AD can be difficult to manage and may require a combination of non-pharmacological and pharmacological approaches. The latter is complicated by FDA “black-box warnings” for the medication classes most often used to target these symptoms, and currently there are initiatives in place to limit their use. In this review, we describe common behavioral symptoms of AD—with a particular focus on the challenging symptoms of “agitation” and “irritability”—and discuss evidence-based approaches to their management. Ultimately, multidimensional approaches must be tailored to the patient and their environment, though evidence-based practices should define the treatment of agitation and irritability in AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Alzheimer’s A. 2015 Alzheimer’s disease facts and figures. Alzheimers Dement. 2015;11:332–84.

    Article  Google Scholar 

  2. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.

    PubMed Central  CAS  PubMed  Google Scholar 

  3. Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol. 2009;5:210–20.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Cohen-Mansfield J. Measurement of inappropriate behavior associated with dementia. J Gerontol Nurs. 1999;25:42–51.

    Article  CAS  PubMed  Google Scholar 

  5. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–14.

    Article  CAS  PubMed  Google Scholar 

  6. Landes AM, Sperry SD, Strauss ME, Geldmacher DS. Apathy in Alzheimer’s disease. J Am Geriatr Soc. 2001;49:1700–7.

    Article  CAS  PubMed  Google Scholar 

  7. Rea R, Carotenuto A, Fasanaro AM, Traini E, Amenta F. Apathy in Alzheimer’s disease: any effective treatment? ScientificWorldJournal. 2014;2014:421385.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Mayor S. Signs of depression and apathy precede memory problems in Alzheimer’s disease, study shows. BMJ. 2015;350:h190.

    Article  PubMed  Google Scholar 

  9. Mograbi DC, Morris RG. On the relation among mood, apathy, and anosognosia in Alzheimer’s disease. J Int Neuropsychol Soc. 2014;20:2–7.

    Article  PubMed  Google Scholar 

  10. Van der Mussele S, Le Bastard N, Saerens J, Somers N, Marien P, Goeman J, et al. Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer’s dementia. Aging Ment Health. 2015;19:247–57.

    Article  PubMed  Google Scholar 

  11. Charernboon T, Phanasathit M. Prevalence of neuropsychiatric symptoms in Alzheimer’s disease: a cross-sectional descriptive study in Thailand. J Med Assoc Thail. 2014;97:560–5.

    Google Scholar 

  12. Thyrian JR, Eichler T, Hertel J, Wucherer D, Dreier A, Michalowsky B, Killimann I, Teipel S, Hoffmann W. Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care: results of the DelpHi-study. J Alzheimers Dis. 2015.

  13. Kales HC, Gitlin LN, Lyketsos CG, Detroit Expert Panel on A, Management of Neuropsychiatric Symptoms of D. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62:762–9. Recommendations from expert panel, with excellent review of the DICE approach.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Conde-Sala JL, Turro-Garriga O, Pinan-Hernandez S, Portellano-Ortiz C, Vinas-Diez V, Gascon-Bayarri J, Rene-Ramirez R. Effects of anosognosia and neuropsychiatric symptoms on the quality of life of patients with Alzheimer’s disease: a 24-month follow-up study. Int J Geriatr Psychiatry. 2015.

  15. Lee D, Heo SH, Yoon SS, Chang DI, Lee S, Rhee HY, et al. Sleep disturbances and predictive factors in caregivers of patients with mild cognitive impairment and dementia. J Clin Neurol. 2014;10:304–13.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Morris S, Patel N, Baio G, Kelly L, Lewis-Holmes E, Omar RZ, et al. Monetary costs of agitation in older adults with Alzheimer’s disease in the UK: prospective cohort study. BMJ Open. 2015;5:e007382.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Peters ME, Schwartz S, Han D, Rabins PV, Steinberg M, Tschanz JT, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015;172:460–5. Recently published analysis of data from the Cache County Dementia Progression Study, examining the relationship between neuropsychiatric symptoms and progression to severe dementia or death.

    Article  PubMed  Google Scholar 

  18. Stevens JR, Jarrahzadeh T, Brendel RW, Stern TA. Strategies for the prescription of psychotropic drugs with black box warnings. Psychosomatics. 2014;55:123–33. Excellent review and discussion of strategies for prescribing agents with block-box warnings.

    Article  PubMed  Google Scholar 

  19. Borisovskaya A, Pascualy M, Borson S. Cognitive and neuropsychiatric impairments in Alzheimer’s disease: current treatment strategies. Curr Psychiatry Rep. 2014;16:470.

    Article  PubMed  Google Scholar 

  20. Soto M, Andrieu S, Nourhashemi F, Ousset PJ, Ballard C, Robert P, Vellas B, Lyketsos CG, Rosenberg PB Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. Int Psychogeriatr. 2014;1–17.

  21. Stella F, Forlenza OV, Laks J, de Andrade LP, de Castilho Cacao J, Govone JS, de Medeiros K, Lyketsos CG. Caregiver report versus clinician impression: disagreements in rating neuropsychiatric symptoms in Alzheimer’s disease patients. Int J Geriatr Psychiatry. 2015.

  22. Brodaty H, Connors MH, Xu J, Woodward M, Ames D, group Ps. The course of neuropsychiatric symptoms in dementia: a 3-year longitudinal study. J Am Med Dir Assoc. 2015;16:380–7.

    Article  PubMed  Google Scholar 

  23. Morra LF, Donovick PJ. Clinical presentation and differential diagnosis of dementia with Lewy bodies: a review. Int J Geriatr Psychiatry. 2014;29:569–76.

    Article  CAS  PubMed  Google Scholar 

  24. Bott NT, Radke A, Stephens ML, Kramer JH. Frontotemporal dementia: diagnosis, deficits and management. Neurodegener Dis Manag. 2014;4:439–54.

    Article  PubMed  Google Scholar 

  25. Cummings JL, Isaacson RS, Schmitt FA, Velting DM. A practical algorithm for managing Alzheimer’s disease: what, when, and why? Ann Clin Transl Neurol. 2015;2:307–23.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Weiner MF. Impact of delirium on the course of Alzheimer disease. Arch Neurol. 2012;69:1639–40.

    Article  PubMed  Google Scholar 

  27. Ballard C, O’Brien J. Treating behavioural and psychological signs in Alzheimer’s disease. BMJ. 1999;319:138–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Staedtler AV, Nunez D. Nonpharmacological therapy for the management of neuropsychiatric symptoms of Alzheimer’s disease: linking evidence to practice. Worldviews Evid-Based Nurs. 2015;12:108–15.

    Article  PubMed  Google Scholar 

  29. Karel MJ, Teri L, McConnell E, Visnic S, Karlin BE. Effectiveness of expanded implementation of STAR-VA for managing dementia-related behaviors among veterans. Gerontologist. 2015.

  30. Gitlin LN, Mann WC, Vogel WB, Arthur PB. A non-pharmacologic approach to address challenging behaviors of Veterans with dementia: description of the tailored activity program-VA randomized trial. BMC Geriatr. 2013;13:96.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Figueiro MG, Plitnick BA, Lok A, Jones GE, Higgins P, Hornick TR, et al. Tailored lighting intervention improves measures of sleep, depression, and agitation in persons with Alzheimer’s disease and related dementia living in long-term care facilities. Clin Interv Aging. 2014;9:1527–37.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Burns A, Perry E, Holmes C, Francis P, Morris J, Howes MJ, et al. A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2011;31:158–64.

    Article  CAS  PubMed  Google Scholar 

  33. Raglio A, Bellandi D, Baiardi P, Gianotti M, Ubezio MC, Zanacchi E, et al. Effect of active music therapy and individualized listening to music on dementia: a multicenter randomized controlled trial. J Am Geriatr Soc. 2015;63:1534–9.

    Article  PubMed  Google Scholar 

  34. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry. 2001;9:361–81.

    Article  CAS  PubMed  Google Scholar 

  35. Padilla R. Effectiveness of environment-based interventions for people with Alzheimer’s disease and related dementias. Am J Occup Ther. 2011;65:514–22.

    Article  PubMed  Google Scholar 

  36. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355:1525–38.

    Article  CAS  PubMed  Google Scholar 

  37. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–43.

    Article  CAS  PubMed  Google Scholar 

  38. FDA U. U.S. Government. 2008.

  39. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170:96–103.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Singh RR, Nayak R. Impact of FDA black box warning on psychotropic drug use in noninstitutionalized elderly patients diagnosed with dementia: a retrospective study. J Pharm Pract. 2015.

  41. Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72:438–45. Recent retrospective case–control study suggesting that the effect of antipsychotics on mortality in elderly patients with dementia may be higher than previously reported.

    Article  PubMed  Google Scholar 

  42. Ma H, Huang Y, Cong Z, Wang Y, Jiang W, Gao S, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42:915–37.

    PubMed  Google Scholar 

  43. M M, AR M, J H, Z W, R S, PG S, B R, L H, MJ S, BA E, A M, T. P. Agency for Healthcare Research and Quality (US), Rockville, MD. 2011.

  44. Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012;169:900–6.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Murray PS, Kumar S, Demichele-Sweet MA, Sweet RA. Psychosis in Alzheimer’s disease. Biol Psychiatry. 2014;75:542–52. Comprehensive review of the “AD with Psychosis” (AD + P) phenotype of Alzheimer’s disease.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Koppel J, Greenwald BS. Optimal treatment of Alzheimer’s disease psychosis: challenges and solutions. Neuropsychiatr Dis Treat. 2014;10:2253–62.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Moore AR, O’Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15:15–28.

    Article  CAS  PubMed  Google Scholar 

  48. Pariente A, Dartigues JF, Benichou J, Letenneur L, Moore N, Fourrier-Reglat A. Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging. 2008;25:61–70.

    Article  CAS  PubMed  Google Scholar 

  49. Carriere I, Fourrier-Reglat A, Dartigues JF, Rouaud O, Pasquier F, Ritchie K, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med. 2009;169:1317–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Berryman SN, Jennings J, Ragsdale S, Lofton T, Huff DC, Rooker JS. Beers criteria for potentially inappropriate medication use in older adults. Medsurg Nurs. 2012;21:129–32. Quiz 133. Important update to Beers Criteria from the American Geriatrics Society, highlighting medications that should be prescribed with caution in the older adult population.

    PubMed  Google Scholar 

  51. Pauszek ME. Propranolol for treatment of agitation in senile dementia. Indiana Med. 1991;84:16–7.

    CAS  PubMed  Google Scholar 

  52. Hersch EC, Falzgraf S. Management of the behavioral and psychological symptoms of dementia. Clin Interv Aging. 2007;2:611–21.

    PubMed Central  PubMed  Google Scholar 

  53. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311:682–91. Results from the CiTAD clinical trial, showing that citalopram significantly reduced agitation in individuals with Alzheimer’s disease (as compared to placebo).

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Suzuki H, Gen K. Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used psychotropic drugs in Alzheimer’s disease with behavioural and psychological symptoms of dementia: a preliminary open-label trial. Psychogeriatrics. 2015;15:32–7.

    Article  PubMed  Google Scholar 

  55. Porsteinsson AP, Smith JS, Keltz MA, Antonsdottir IM. Can antidepressant medication relieve agitation in Alzheimer’s disease? Expert Rev Neurother. 2014;14:969–71.

    Article  CAS  PubMed  Google Scholar 

  56. Ballard C, Thomas A, Gerry S, Yu LM, Aarsland D, Merritt C, et al. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer’s disease (MAIN-AD). J Am Med Dir Assoc. 2015;16:316–22.

    Article  PubMed  Google Scholar 

  57. Voyer P, McCusker J, Cole MG, Monette J, Champoux N, Ciampi A, et al. Behavioral and psychological symptoms of dementia: how long does every behavior last, and are particular behaviors associated with PRN antipsychotic agent use? J Gerontol Nurs. 2015;41:22–37. quiz 38–29.

    Article  PubMed  Google Scholar 

  58. Neumann RD, Faris P, Klassen R. Examining trends in the administration of “as needed” medications to inpatients with behavioral and psychological symptoms of dementia. Am J Alzheimers Dis Other Demen. 2015;30:247–56.

    Article  PubMed  Google Scholar 

  59. Martin D, MacVicar S. Drugging dementia: are antipsychotics killing nursing home patients? Aljazeera America. 2015.

  60. CMS. Center for Medicare & Medcaid Services, CMS.gov. 2014.

  61. Mort JR, Sailor R, Hintz L. Partnership to decrease antipsychotic medication use in nursing homes: impact at the state level. S D Med. 2014;67:67–9.

    PubMed  Google Scholar 

  62. Glezer A, Stern TA, Mort EA, Atamian S, Abrams JL, Brendel RW. Documentation of decision-making capacity, informed consent, and health care proxies: a study of surrogate consent. Psychosomatics. 2011;52:521–9.

    Article  PubMed  Google Scholar 

  63. Volicer L. Goals of care in advanced dementia: quality of life, dignity and comfort. J Nutr Health Aging. 2007;11:481.

    CAS  PubMed  Google Scholar 

  64. Brendel RW, Wei MH, Schouten R, Edersheim JG. An approach to selected legal issues: confidentiality, mandatory reporting, abuse and neglect, informed consent, capacity decisions, boundary issues, and malpractice claims. Med Clin N Am. 2010;94:1229–40. xi-ii. Review of approaches to common medicolegal issues, including capacity decisions and informed consent.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

    Aaron M. Koenig

  2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

    Aaron M. Koenig

  3. MassGeneral Institute for Neurodegenerative Disease, Boston, MA, USA

    Steven E. Arnold

  4. Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

    Steven E. Arnold

  5. Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA

    Joel E. Streim

  6. Behavioral Health Service, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA

    Joel E. Streim

Authors
  1. Aaron M. Koenig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven E. Arnold
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joel E. Streim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aaron M. Koenig.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Support

This work was supported, in part, by National Institutes of Health grant T32 MH1711929 (AMK).

Additional information

This article is part of the Topical Collection on Geriatric Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koenig, A.M., Arnold, S.E. & Streim, J.E. Agitation and Irritability in Alzheimer’s Disease: Evidenced-Based Treatments and the Black-Box Warning. Curr Psychiatry Rep 18, 3 (2016). https://doi.org/10.1007/s11920-015-0640-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11920-015-0640-7

Keywords

Search

Navigation